Видео ютуба по тегу T-Dxd

Predictive biomarkers for T-DXd response in metastatic breast cancer
Predictive biomarkers for T-DXd response in metastatic breast cancer
Choosing between tucatinib and T-DXd in HER2+ breast cancer
Choosing between tucatinib and T-DXd in HER2+ breast cancer
Трастузумаб дерукстекан при раке молочной железы | NEJM
Трастузумаб дерукстекан при раке молочной железы | NEJM
T-DXd против T-DM1 при HER2+ раке молочной железы высокого риска: промежуточные данные DESTINY-Br...
T-DXd против T-DM1 при HER2+ раке молочной железы высокого риска: промежуточные данные DESTINY-Br...
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
DESTINY-Gastric05: first-line T-DXd ± pembrolizumab in HER2+ gastric cancer
DESTINY-Gastric05: first-line T-DXd ± pembrolizumab in HER2+ gastric cancer
REALITY-01: final results of real-world T-DXd in HER2+ metastatic breast cancer
REALITY-01: final results of real-world T-DXd in HER2+ metastatic breast cancer
HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancer
HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancer
DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC?
DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC?
Dr. Mark Pegram and Dr. Neil Iyengar - T-DXd’s Rise in HER2+ & HER2-Low Breast Cancer
Dr. Mark Pegram and Dr. Neil Iyengar - T-DXd’s Rise in HER2+ & HER2-Low Breast Cancer
Detecting and Managing T-DXd–Related Interstitial Lung Disease: The Five “S” Rules
Detecting and Managing T-DXd–Related Interstitial Lung Disease: The Five “S” Rules
Оставшиеся вопросы, связанные с использованием T-DXd в лечебных целях
Оставшиеся вопросы, связанные с использованием T-DXd в лечебных целях
Using T-Dxd in a Patient with Lung Metastases: 2023 Best of Breast Conference
Using T-Dxd in a Patient with Lung Metastases: 2023 Best of Breast Conference
Balancing the efficacy and toxicity of T-DXd in early stage breast cancer
Balancing the efficacy and toxicity of T-DXd in early stage breast cancer
Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer
Effectiveness of TDXD vs. Sacituzumab for ER+ Breast Cancer | Jane Meisel, MD | ASCO22 Updates
Effectiveness of TDXD vs. Sacituzumab for ER+ Breast Cancer | Jane Meisel, MD | ASCO22 Updates
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis
Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study
Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study
DESTINY-04: HER2 1+/FISH- Metastatic Breast Cancer TDXD Treatment | Jane Meisel, MD | ASCO22 Updates
DESTINY-04: HER2 1+/FISH- Metastatic Breast Cancer TDXD Treatment | Jane Meisel, MD | ASCO22 Updates
Assessing the real-world side effects of T-DXd in HER2+ breast cancer
Assessing the real-world side effects of T-DXd in HER2+ breast cancer
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
Dr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment
Dr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment
Is T-DXd + Pertuzumab the New FirstLine Standard? - Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin
Is T-DXd + Pertuzumab the New FirstLine Standard? - Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin
Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ Pharmacology
Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ Pharmacology
Rethinking HER2-Positive Breast Cancer Treatment Regimens with T-DXd
Rethinking HER2-Positive Breast Cancer Treatment Regimens with T-DXd